{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/676867bc15b961464553ab2f/67b60223d24f7fcce86a47a0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"#24: US Pharma and Life Sciences Deals: 2025","description":"<p>The pharmaceutical and life sciences sector anticipates a surge in merger and acquisition activity in 2025<strong>.</strong>&nbsp;Driving this trend are expected interest rate reductions by the Federal Reserve and the resolution of post-election uncertainties. While deal values and volumes are projected to rise, transactions in the $5 billion to $15 billion range are forecasted to be the most common. However, geopolitical issues could present obstacles to this growth.</p><p><br></p><p><br></p><p><br></p>","author_name":"Dr. Kesha Chauhan, MD"}